Goldman Sachs, Silence Therapeutics and Sell Recommendation

Silence Therapeutics hit with new Sell at Goldman Sachs on resource constraints
Silence Therapeutics (SLN) stock was initiated by Goldman Sachs with a Sell recommendation citing potential funding challenges for the company. Read more here.
Goldman Sachs Initiates Coverage of Silence Therapeutics plc - Depositary Receipt () (SLN) with Sell Recommendation
Fintel reports that on February 11, 2025, Goldman Sachs initiated coverage of Silence Therapeutics plc - Depositary Receipt () (NasdaqGM:SLN) with a Sell recommendation. Analyst Price Forecast Suggests 699.
Goldman starts Silence Therapeutics at Sell on ‘undifferentiated’ data
Goldman Sachs initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target The company is developing siRNA
The Goldman Sachs Group Initiates Coverage on Silence Therapeutics (NASDAQ:SLN)
Stock analysts at The Goldman Sachs Group began coverage on shares of Silence Therapeutics (NASDAQ:SLN – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports.
Goldman Sachs cuts Silence Therapeutics stock rating to Sell
On Tuesday, Goldman Sachs initiated coverage on Silence Therapeutics (NASDAQ:SLN), currently trading at $4.92 with a market cap of $232.3 million, with a Sell rating and a price target of $6.00.
Silence Therapeutics initiated with a Sell at Goldman Sachs
Goldman Sachs analyst Richard Law initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target Maximize Your
Analysts Set Silence Therapeutics plc (NASDAQ:SLN) PT at $54.75
Silence Therapeutics plc (NASDAQ:SLN – Get Free Report) has received an average recommendation of “Buy” from the six ratings ...
Nasdaq10d
Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings)
7 analysts have expressed a variety of opinions on Silence Therapeutics (NASDAQ:SLN) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides ...
Investing10d
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges
Silence Therapeutics plc (NASDAQ:SLN), a biotechnology company specializing in RNA therapeutics, stands at a crucial juncture in its development pipeline. With promising assets targeting ...